A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience
PURPOSE: Lymphoblastic lymphoma (LBL) is an invasive neoplasm of precursor T-cell or B-cell lineage. A broadly accepted standard treatment for adult LBL has not yet been defined.
MATERIALS AND METHODS: To address this issue, we compared two chemotherapy regimens: a modified non-Hodgkin lymphoma Berlin-Frankfurt-Münster-95 (NHL-BFM-95) regimen and HyperCVAD/MA. This retrospective study consecutively enrolled 207 adult LBL patients at two hospitals from 2000 to 2018. Univariate and multivariate analysis were used to assess prognostic factors.
RESULTS: In the present study, most clinical characteristics were similar between the two treatment groups except for age and lactate dehydrogenase (LDH) level. Patients treated with modified NHL-BFM-95 regimen tended to be younger and with elevated LDH level. The modified NHL-BFM- 95 regimen produced better treatment outcomes than those with HyperCVAD/MA in patients with T-LBL or patients < 40 years. Treatment with HyperCVAD/MA, high Eastern Cooperative Oncology Group scores, and bone marrow involvement were independent risk factors in T-LBL. No patients interrupted treatment for severe adverse events.
CONCLUSION: The results suggested that the modified regimen is well-tolerated and can produce the promising outcomes in patients with T-LBL or patients < 40 years.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Cancer research and treatment - 52(2020), 2 vom: 30. Apr., Seite 573-585 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Chun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adult |
|---|
| Anmerkungen: |
Date Completed 21.12.2020 Date Revised 21.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4143/crt.2019.542 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306141205 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306141205 | ||
| 003 | DE-627 | ||
| 005 | 20231225122718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4143/crt.2019.542 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1020.xml |
| 035 | |a (DE-627)NLM306141205 | ||
| 035 | |a (NLM)32019289 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Chun |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2020 | ||
| 500 | |a Date Revised 21.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Lymphoblastic lymphoma (LBL) is an invasive neoplasm of precursor T-cell or B-cell lineage. A broadly accepted standard treatment for adult LBL has not yet been defined | ||
| 520 | |a MATERIALS AND METHODS: To address this issue, we compared two chemotherapy regimens: a modified non-Hodgkin lymphoma Berlin-Frankfurt-Münster-95 (NHL-BFM-95) regimen and HyperCVAD/MA. This retrospective study consecutively enrolled 207 adult LBL patients at two hospitals from 2000 to 2018. Univariate and multivariate analysis were used to assess prognostic factors | ||
| 520 | |a RESULTS: In the present study, most clinical characteristics were similar between the two treatment groups except for age and lactate dehydrogenase (LDH) level. Patients treated with modified NHL-BFM-95 regimen tended to be younger and with elevated LDH level. The modified NHL-BFM- 95 regimen produced better treatment outcomes than those with HyperCVAD/MA in patients with T-LBL or patients < 40 years. Treatment with HyperCVAD/MA, high Eastern Cooperative Oncology Group scores, and bone marrow involvement were independent risk factors in T-LBL. No patients interrupted treatment for severe adverse events | ||
| 520 | |a CONCLUSION: The results suggested that the modified regimen is well-tolerated and can produce the promising outcomes in patients with T-LBL or patients < 40 years | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Lymphoblastic lymphoma | |
| 650 | 4 | |a Modified NHL-BFM-95 regimen | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Wuxiao, Zhi-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaoqin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Guanjun |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Zhongjun |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research and treatment |d 2001 |g 52(2020), 2 vom: 30. Apr., Seite 573-585 |w (DE-627)NLM190743158 |x 2005-9256 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2020 |g number:2 |g day:30 |g month:04 |g pages:573-585 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4143/crt.2019.542 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2020 |e 2 |b 30 |c 04 |h 573-585 | ||